抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展 点击下载
论文标题: 抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展
英文标题:
中文摘要: 化疗相关性腹泻(CRD)可导致治疗效果和患者依从性降低,影响肿瘤患者的长期治疗结局,甚至危及生命。除传统化疗药物外,许多分子靶向药物也可导致CRD,包括小分子表皮生长因子受体(EGFR)抑制剂、抗EGFR单克隆抗体、磷酸肌醇3-激酶抑制剂、血管内皮细胞生长因子受体小分子抑制剂、BCR-ABL1和KIT抑制剂、人表皮生长因子受体2靶点抑制剂、周期蛋白依赖性激酶抑制剂、抗体-药物偶联物等多种分子靶向药物。其发生机制可能与分子靶向治疗药物引起肠黏膜损伤或肠炎等有关,临床表现为大便频率增加和/或松散不成形,患者常伴有产气过多和/或肠绞痛。不同药物引起的CRD发生率不同,临床应重视病史采集和鉴别诊断,积极干预并进行动态评估,加强患者教育,以及时发现和预防肠毒性的发生。
英文摘要: Diarrhea caused by chemotherapy is called chemotherapy-related diarrhea (CRD). CRD can lead to reduced treatment effectiveness and compliance, affect the long-term outcome of tumor patients, and can be life-threatening in severe cases. In addition to conventional chemotherapy drugs, many molecularly targeted drugs are also associated with CRD, including small molecule epidermal growth factor receptor (EGFR) inhibitors, anti-EGFR monoclonal antibodies, phosphoinositide 3-kinase inhibitors, small molecule inhibitors of vascular endothelial growth factor receptor, BCR-ABL1 and KIT inhibitors, human epidermal growth factor receptor 2 target inhibitors, cyclin-dependent protein kinase inhibitors, antibody-drug conjugates and other molecularly targeted drugs. The occurrence mechanism may be related to the intestinal mucosal injury or enteritis caused by molecularly targeted drugs. The clinical manifestations are increased stool frequency and/or loose imposition, and patients are often associated with excess hyperproduction and/or colic. The incidence of CRD varies with different drugs. Great importance should be attached to collecting medical history and differential diagnosis, actively intervening and conducting dynamic evaluation, strengthening patient education, and timely detecting and preventing the occurrence of intestinal toxicity.
期刊: 2024年第35卷第04期
作者: 孙雪林;郑丽;李鸿升;胡欣;张亚同
英文作者: SUN Xuelin,ZHENG Li,LI Hongsheng,HU Xin,ZHANG Yatong
关键字: 化疗相关性腹泻;肿瘤;靶向治疗;肠毒性;不良反应
KEYWORDS: chemotherapy-related diarrhea; tumor; targeted therapy; intestinal toxicity; adverse drug reactions
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!